Off-label reports of new biologics: Exciting new therapy or dubious research? Examples from recombinant activated factor VII

Journal of Intensive Care Medicine

Volumn 21, Issue 1, 2006, Pages 54-59

  Dzik, Walter H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; GABAPENTIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; BLOOD TRANSFUSION; BRAIN EDEMA; BRAIN HEMORRHAGE; CLINICAL RESEARCH; CLINICAL TRIAL; CRIME; DEATH; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; EXPERIMENTATION; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HEMOSTASIS; HUMAN; INTENSIVE CARE; LAW SUIT; LEGAL ASPECT; MEDICAID; MEDICAL ETHICS; MEDICARE; MENTAL DISEASE; MORTALITY; OFF LABEL DRUG USE; PATIENT CARE; PEER PRESSURE; PEER REVIEW; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; PUBLICATION; REIMBURSEMENT; REVIEW; REWARD; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR; UNSPECIFIED SIDE EFFECT; VALIDITY;

ATTITUDE OF HEALTH PERSONNEL; BIOLOGICAL PRODUCTS; DRUG APPROVAL; DRUG EVALUATION; DRUG LABELING; DRUGS, INVESTIGATIONAL; ETHICS, CLINICAL; FACTOR VIIA; HUMANS; MOTIVATION; UNITED STATES;

EID: 33644974700     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066605285223     Document Type: Review

References (25)

1. Adams C, Young A. Drug-makers' promotions boost off-label use by doctors. Knight Ridder Newspapers. Available at: http://www.realcities.com/mld/ krwashington/news/special_packages/riskyrx/. Accessed November 3, 2003.
2. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ. 2000;320:79-82.
3. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33:883-890.
4. Grounds RM, Seebach C, Knoth C, et al. Use of recombinant activated factor VII (Novoseven) in trauma and surgery: analysis of outcomes reported to an international registry. J Intensive Care Med. 2006;21:27-39. Accessed May 2005.
5. Wood JJ, O'Connell KA, Wise RP. Post-licensure safety surveillance for recombinant human coagulation factor VIIa. CBER, FDA, Rockville, MD Board Number: H-34. Available at: http://www.accessdata.fda.gov/scripts/oc/ scienceforum/sf2005/Search/preview.cfm?abstract_id=62&backto=author. Accessed May 2005.
6. Cohen S, Diringer M, Dubois R, et al. Evidence and consensus-based recommendations for the use of recombinant activated human factor VII (rVIIa) therapy. University Health Consortium and Society for the Advancement of Blood Management. Available at: www.uhc.edu. Accessed May 2005.
7. Edwards P, Arango M, Balica L, et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet. 2005;365:1957-1959.
8. Lodge JP, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology. 2005;102:269-275.
9. Planinsic RM, Testa G, Sukru E, et al. Safety and efficacy of single bolus close of recombinant factor VIIa in patients undergoing orthotopic liver transplantation: a randomized multi-center study (abstract). Hepatology. 2002;36:660a.
10. Lodge JP, Jonas S, Jones RM, et al. Efficacy and safety of recombinant factor VIIa (rFVIIa) on transfusion reduction in orthotopic liver transplantation (OLT) - a randomized, double-blind, placebo-controlled trial (abstract). Transplantation. 2004;78(suppl 1):93.
11. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet. 2003;361:201-205.
12. Mayer SA, Brun MC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-785.
13. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patient with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004;127:1123-1130.
14. Raobaikady R, Redman J, Ball JA, Maloney G, Grounds RM. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br J Anaesth. 2005:94;586-591.
15. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8-18.
16. Pihusch M, Bacigalupo A, Szer J, et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost. 2005;3:1935-1944.
17. Brown DL, Morgenstern LB. Stopping the bleeding in intracerebral hemorrhage. N Engl J Med. 2005;352:828-830.
18. Topol EJ. Nesiritide - not verified. N Engl J Med. 2005;353:113-115.
19. Blum RS. Legal considerations in off-label medication prescribing. Arch Intern Med. 2002;162:1777-1779.
20. Reinhardt UE. An information infrastructure for the pharmaceutical market. Health Affairs. 2004;23:107-112.
21. Angell M. The truth about the drug companies. New York, NY: Random House, 2004.
22. Mehlman MJ. Off-label prescribing. The doctor will see you now. Available at: http://www.thedoctorwillseeyounow.com/articles/bioethics/offlabel_11. Accessed May 2005.
23. Information available at: http://www.phillipsandcohen.com/CM/ NewsSettlements/TAP_Oct3_2001.asp. Accessed May 2005.
24. Sterns DJ. Re: Lupron® marketing and sales practices litigation. Order granting preliminary approval of settlement, certifying class for purposes of settlement, directing notice to the class and scheduling fairness hearing. US District Court, District of Massachusetts MDL No. 1430 File No 01-CV-10861-RGS. 2004.
25. Lenzer J. Pfizer pleads guilty, but drug sales continue to soar. BMJ. 2004;328:1217.